LQDALiquidia

Each row is one issuer’s token for Liquidia, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.

Tokenized versions of Liquidia, the issuer behind each, the chains it is deployed on, and what these wallets hold of it.

Token	Issuer	Chains	You hold
rLQDA	Reality	ARB	—

Deployments come from the instrument registry, generated 2026-09-30. A chain listed here is one the issuer has deployed on, not a promise that a market exists on it.

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Type

Common stock

Sector

Healthcare › Biotechnology

Exchange

Nasdaq

Listed since

Jul 26, 2018

Shares outstanding

89.51M

Employees

216

As the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.